Cargando…
Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results
BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806295/ https://www.ncbi.nlm.nih.gov/pubmed/20025752 http://dx.doi.org/10.1186/1748-717X-4-67 |
_version_ | 1782176273172267008 |
---|---|
author | Guckenberger, Matthias Wulf, Joern Thalheimer, Andreas Wehner, Daniel Thiede, Arnulf Müller, Gottfried Sailer, Marco Flentje, Michael |
author_facet | Guckenberger, Matthias Wulf, Joern Thalheimer, Andreas Wehner, Daniel Thiede, Arnulf Müller, Gottfried Sailer, Marco Flentje, Michael |
author_sort | Guckenberger, Matthias |
collection | PubMed |
description | BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) with pathological proven rectal cancer (clinical stage II 50%, III 41.5%, IV 8.5%) were treated preoperatively with twice daily radiotherapy of 2.9 Gy single fraction dose to a total dose of 29 Gy; surgery was performed immediately in the following week with total mesorectal excision (TME). Adjuvant 5-FU based chemotherapy was planned for pathological stage UICC ≥ II. RESULTS: After low anterior resection (70%) and abdominoperineal resection (30%), pathology showed stage UICC I (27.1%), II (25.4%), III (37.3%) and IV (9.3%). Perioperative mortality was 3.4% and perioperative complications were observed in 22.8% of the patients. Adjuvant chemotherapy was given in 75.3% of patients with pathological stage UICC ≥ II. After median follow-up of 46 months, five-year overall survival was 67%, cancer-specific survival 76%, local control 92% and freedom from systemic progression 75%. Late toxicity > grade II was observed in 11% of the patients. CONCLUSIONS: Preoperative short-course radiotherapy, total mesorectal excision and adjuvant chemotherapy for pathological stage UICC ≥ II achieved excellent local control and favorable survival. |
format | Text |
id | pubmed-2806295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28062952010-01-14 Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results Guckenberger, Matthias Wulf, Joern Thalheimer, Andreas Wehner, Daniel Thiede, Arnulf Müller, Gottfried Sailer, Marco Flentje, Michael Radiat Oncol Research BACKGROUND: To evaluate clinical outcome after preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy and adjuvant chemotherapy for pathological stage UICC ≥ II. METHODS: 118 patients (median age 64 years; male : female ratio 2.5 : 1) with pathological proven rectal cancer (clinical stage II 50%, III 41.5%, IV 8.5%) were treated preoperatively with twice daily radiotherapy of 2.9 Gy single fraction dose to a total dose of 29 Gy; surgery was performed immediately in the following week with total mesorectal excision (TME). Adjuvant 5-FU based chemotherapy was planned for pathological stage UICC ≥ II. RESULTS: After low anterior resection (70%) and abdominoperineal resection (30%), pathology showed stage UICC I (27.1%), II (25.4%), III (37.3%) and IV (9.3%). Perioperative mortality was 3.4% and perioperative complications were observed in 22.8% of the patients. Adjuvant chemotherapy was given in 75.3% of patients with pathological stage UICC ≥ II. After median follow-up of 46 months, five-year overall survival was 67%, cancer-specific survival 76%, local control 92% and freedom from systemic progression 75%. Late toxicity > grade II was observed in 11% of the patients. CONCLUSIONS: Preoperative short-course radiotherapy, total mesorectal excision and adjuvant chemotherapy for pathological stage UICC ≥ II achieved excellent local control and favorable survival. BioMed Central 2009-12-21 /pmc/articles/PMC2806295/ /pubmed/20025752 http://dx.doi.org/10.1186/1748-717X-4-67 Text en Copyright ©2009 Guckenberger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Guckenberger, Matthias Wulf, Joern Thalheimer, Andreas Wehner, Daniel Thiede, Arnulf Müller, Gottfried Sailer, Marco Flentje, Michael Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title_full | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title_fullStr | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title_full_unstemmed | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title_short | Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results |
title_sort | prospective phase ii study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 gy to a total dose of 29 gy - long-term results |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806295/ https://www.ncbi.nlm.nih.gov/pubmed/20025752 http://dx.doi.org/10.1186/1748-717X-4-67 |
work_keys_str_mv | AT guckenbergermatthias prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT wulfjoern prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT thalheimerandreas prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT wehnerdaniel prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT thiedearnulf prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT mullergottfried prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT sailermarco prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults AT flentjemichael prospectivephaseiistudyofpreoperativeshortcourseradiotherapyforrectalcancerwithtwicedailyfractionsof29gytoatotaldoseof29gylongtermresults |